Document:

EXHIBIT 10.10
                                                                   -------------

                         EXECUTIVE EMPLOYMENT AGREEMENT

     THIS EXECUTIVE EMPLOYMENT AGREEMENT (the "Agreement") is made and entered
into as of the 1st day of May, 2003 by and among

                           Vitalstate Inc.
                           2191 Hampton Avenue
                           Montreal, Quebec H4A 2K5
                           Canada,                          (the "Corporation")

                                    and

                           Terry Giles
                           2012 White Coral Court
                           Wellington, FL
                           33414
                                                            (the "Executive")

     WHEREAS the Corporation is engaged in the business of the creation,
production, sale and marketing of nutraceuticals (hereinafter the "Business");

     WHEREAS the Corporation wishes to employ the Executive as its chief
operating officer and president of a corporate subsidiary named Vitalstate US,
Inc. (the "Subsidiary"), and the Executive agrees to be so employed, in
accordance with terms, covenants and conditions hereinafter set forth;

     NOW, THEREFORE, FOR THE REASONS SET FORTH ABOVE, AND IN CONSIDERATION OF
THE MUTUAL PREMISES AND AGREEMENTS HEREINAFTER SET FORTH, THE PARTIES HERETO
ACKNOWLEDGE AND AGREE AS FOLLOWS:

1.   NATURE AND TERM OF SERVICES
     ---------------------------

1.1 The Corporation hereby employs, engages and hires the Executive as chief
operating officer of Vitalstate Inc. and president of the Subsidiary, and the
Executive hereby accepts and agrees to such hiring, engagement and employment.
Hereinafter, where context requires, reference to the Corporation includes
reference to the Subsidiary.

1.2 NATURE OF SERVICES. The Executive agrees that he shall provide his services
to the Corporation on a full-time basis, the whole according to the terms and
conditions hereinafter set forth, as an Executive to the Corporation, and his
duties as such an Executive shall include, but not be limited to, those set
forth from time to time by the Corporation's board of directors. The services to
be performed by the Executive hereunder shall be principally performed from the
Corporation's Florida facility (hereinafter the "Services").

                                       1
<PAGE>

1.3 TERM. The term of this Agreement (the "Term") shall commence May 1, 2003 and
shall continue for a 3 year term ending on April 30, 2006. The Term shall be
renewable, at the option of the Executive, for up to 2 successive 1 year
periods, by Executive's giving written notice to the Corporation of his intent
to extend the Term for an additional year, not less than sixty (60) days prior
to the end of the existing Term. The Term, including any extensions thereof, is
subject to earlier termination as provided herein.

2.   COMPENSATION
     ------------

2.1 SALARY. In consideration for the Services to be rendered pursuant to this
Agreement, and in further consideration for the confidentiality, non-competition
and non-solicitation covenants described in Article 3 hereof, the Corporation
shall pay the Executive an initial base annual salary of USD$200,000 per annum
(hereinafter the "Salary") subject to the normal deductions at source, payable
in semi-weekly installments. During the Term, the annual base Salary shall be
reviewed periodically by the Corporation for possible increase.

2.2 BONUSES. Executive will be eligible to receive an annual bonus payable in
cash an amount representing five percent (5%) of the net profits of the
Corporation and options of Vitalstate Inc. at the Executive 1 level.

2.3 SIGNING BONUS. In connection with this Agreement, the Corporation agrees to
issue 250,000 restricted shares of Vitalstate Inc. common stock (the
"Compensation Shares") to the Executive as a signing bonus, 83,334 of which will
be issuable upon the execution of this Agreement, 83,333 of which will be
issuable upon the first anniversary of this Agreement, and 83,333 of which shall
be payable upon the second anniversary of this Agreement.

2.4 OTHER BENEFITS. Executive shall also be eligible to participate in any
benefit programs of the Corporation, including but not limited to life,
disability or health insurance, pension, retirement or other benefit plans
adopted by the Corporation for the general and overall benefit of all executive
and key employees of the Corporation. In this regard, health and life insurance
policies, if any, covering all such executive officers and key employees will be
paid for at the sole expense of the Corporation. An additional life insurance
policy in the name of Terry Giles and in the amount of USD$1,000,000 will be
paid for by the Corporation.

2.5 EXPENSE REIMBURSEMENT. The Corporation will reimburse the Executive for all
documented and approved expenses incurred by the Executive in the performance of
his duties under this Agreement, to be paid in accordance with the Corporation's
practices in effect from time to time.

3.   CONFIDENTIAL INFORMATION AND NON-COMPETITION
     --------------------------------------------

3.1 DEFINITION OF CONFIDENTIAL INFORMATION. For the purposes of this Agreement,
the term "Confidential Information" shall mean, but shall not be limited to, any
technical or non-technical data, formulae, patterns, compilations, programs,
patents, trade secrets, devices, methods, techniques, drawings, designs,
processes, procedures, improvements, models, experimental work, manuals,
financial data, financial information, business forecast information, cash
requirement information, organization information, valuation information,
technical information, scientific information, research information, lists of
actual or potential customers or suppliers, of the

                                       2
<PAGE>

Corporation and any information regarding any of the Corporation's marketing,
sales or dealer network, which is not generally known to the public through
legitimate origins. The Corporation and the Executive acknowledge and agree that
such Confidential Information is extremely valuable to the Corporation. In the
event that any part of the Confidential Information becomes generally known to
the public through legitimate origins (other than by breach of this Agreement by
the Executive), that part of the Confidential Information shall no longer be
deemed Confidential Information for the purposes of this Agreement, but the
Executive shall continue to be bound by the terms of this Agreement as to all
other Confidential Information.

3.2 NON-DISCLOSURE OF CONFIDENTIAL INFORMATION. Unless otherwise required by law
or expressly authorized in writing by the Corporation, the Executive shall not,
at any time during or after the Term, directly or indirectly, in any capacity
whatsoever, except in connection with services to be performed hereunder,
divulge, disclose or communicate to any person, moral or physical, entity, firm
or any other third party, or utilize for the Executive's personal benefit or for
the benefit of any competitor of the Corporation, any Confidential Information.

3.3 DELIVERY UPON TERMINATION. Confidential Information and all embodiments
thereof (including any information on computer disk and any reproductions) shall
remain the sole property of the Corporation, and immediately upon request to
this effect or immediately upon termination of this Agreement for any reason,
the Executive shall promptly deliver to the Corporation all correspondence,
drawings, manuals, letters, notes, notebooks, reports, programs, plans,
proposals, financial documents, or any other documents concerning the
Corporation's customers, dealer network, marketing strategies, products and/or
processes which contain Confidential Information.

3.4 COVENANT NOT TO COMPETE. During the Term (as previously defined in 1.3), and
for a period of twelve (12) months after the termination of the Agreement (as
per section 4.3), the Executive shall not, on his own behalf or on behalf of
another, either alone or in combination with others, directly or indirectly, in
any capacity whatsoever (including, without limitation, as an employee,
employer, principal, agent, joint venture, partner, shareholder or other
equityholder, independent contractor, licensor, licensee, franchisor,
franchisee, distributor, consultant, supplier or trustee):

     (i)  engage anywhere in Canada and the United States of America
          (hereinafter the "Territory") in any aspect of the Business for
          purposes which are competitive with the Business as conducted by the
          Corporation;

     (ii) have any ownership or equity interest in any business, firm,
          corporation, joint venture, partnership or other entity engaged in any
          aspect of the Business in the Territory (other than 5% or less of a
          publicly traded company); or

     (iii) consult with or assist any person, moral or physical (other than the
          Corporation) who or which is engaged in any aspect of the Business in
          the Territory for purposes which are competitive with the Business as
          conducted by the Corporation.

                                       3
<PAGE>

3.5 COVENANT OF NON-SOLICITATION. During the Term (as previously defined in
1.3), and for a period of twelve (12) months after the termination of the
Agreement (as per section 4.3), the Executive shall not, on his own behalf or on
behalf of another, either alone or in combination with others, directly or
indirectly, in any capacity whatsoever (including, without limitation, as an
employee, employer, principal, agent, joint venturer, partner, shareholder, or
other equityholder, independent contractor, licensor, licensee, franchisor,
franchisee, distributor, consultant, supplier or trustee):

     (i)  solicit or assist any third party to solicit any employees of the
          Corporation to become an officer, director, employee or agent of the
          Corporation or such third party, or otherwise entice away from the
          employment of the Corporation any employee of the Corporation; or

     (ii) (a)  canvass or solicit (or procure or assist the canvassing or the
               soliciting of) any customer of the Corporation for purposes which
               are competitive with the Business as conducted by the
               Corporation; or

          (b)  accept (or procure or assist the acceptance of) any business from
               any customer of the Corporation for purposes which are
               competitive with the Business as conducted by the Corporation.

3.6 ASSIGNMENT OF CONSULTATION INVENTIONS. The Executive shall disclose and
assign to the Corporation any and all materials of a proprietary nature,
including, but not limited to, material subject to protection as Confidential
Information, trade secrets or as patentable or copyrightable ideas, which the
Executive may conceive, invent, create or discover, either solely or jointly
with another or others, during the Term, in connection with the rendering of
Services hereunder and which relates to or is capable of use in connection with
the business of the Corporation or any services or products offered, performed,
produced, used, sold or being developed by the Corporation at the time said
material is developed as it pertains to Vitalstate.

3.7 ADDITIONAL DOCUMENTATION. The Executive will, upon request of the
Corporation, either during or at any time after the termination of this
Agreement, execute and deliver all papers, including applications for patents or
copyrights, and do such other acts (solely at the Corporation `s expense) as may
be necessary to obtain and to maintain proprietary rights in the Confidential
Information specified in Section 3.6 above and the materials specified in
Section 3.6 above, in any and all countries and to vest title thereto in the
Corporation.

3.8 OTHER REMEDIES. In the event that the Executive breaches any of the terms
contained in this Section 3, the Executive stipulates that said breach will
result in immediate and irreparable harm to the business and goodwill of the
Corporation and that damages, if any, and remedies at law for such breach would
be inadequate. In addition to any and all such remedies available to the
Corporation, the Corporation shall therefore be entitled to apply for and
receive from any court of competent jurisdiction an injunction to restrain any
violation of this Agreement and for such further relief as the court may deem
just and proper.

                                       4
<PAGE>

3.9 CONTINUING OBLIGATIONS. The obligations, duties and liabilities of the
Executive pursuant to Section 3 of this Agreement are continuing, absolute and
unconditional and shall remain in full force and effect as provided therein
despite any termination of this Agreement for any reason whatsoever, including,
but not limited to, the expiration of the Term.

4.   TERMINATION
     -----------

4.1 TERMINATION FOR CAUSE; DEATH OR DISABILITY OF EXECUTIVE. In the event of a
material breach by the Executive under this Agreement, or upon his death or
permanent disability such that the Executive cannot perform the Services
hereunder, this Agreement may be terminated by the Corporation without notice or
penalty. Notwithstanding the foregoing, any Salary earned by the Executive prior
to such termination, death or disability shall remain payable by the Corporation
to the Executive or his estate. For purposes of this Agreement, permanent
disability means the Executive has been unable, for three consecutive months, to
perform the Executive's duties under this Agreement, as a result of physical or
mental illness or injury. Further, in the event this Agreement is terminated by
the Corporation for cause or is voluntarily terminated by the Executive pursuant
to Section 4.2 below, at any time during the initial three (3) year Term of this
Agreement, Executive shall have to return or forego a proportionate amount of
the 250,000 shares signing bonus provided for in Section 2.3 hereof. By way of
example, if Executive voluntarily terminates this Agreement after two (2) years,
he would have to return or forego 83,333 shares.

4.2 TERMINATION BY EXECUTIVE. This Agreement may be terminated at any time by
Executive upon three (3) months prior written notice to Corporation.

4.3 TERMINATION BY CORPORATION WITHOUT CAUSE OR RESIGNATION WITH GOOD REASON.
Employee will be deemed to have "good reason" to resign in the event: (A) A
reduction in employee's responsibilities or duties. (B) A material breech by the
Corporation of its obligations, under Section 2 of this agreement occurs (C)
Change in control as defined in Section 4.4 of this agreement. In the event this
Executive's employment is voluntarily terminated by the Corporation without
cause, for any reason whatsoever or by the Executive's resignation with good
reason during the Term, the Corporation shall (i) continue to pay Executive an
amount equivalent to his base salary, payable bi-monthly for the duration of the
Term. In the event that termination without cause occurs in the final twelve
months of the Term, payments shall continue until the end of the Term, plus an
additional twelve months (ii) Corporation will continue to pay commissions /
bonuses as defined in Section 2.2 of this agreement (iii) Corporation will
continue to provide executive with benefits as defined in Section 2.3 of the
agreement with all shares of Vitalstate Inc. stock being 100% vested at the
termination date.

4.4 TERMINATION FOLLOWING A CHANGE IN CONTROL. In the event this Agreement is
terminated by the Corporation pursuant to a change in control of Vitalstate
Inc., the Corporation shall (i) continue to pay Executive an amount equivalent
to 2 years of his base salary, payable bi-monthly for the duration of the Term.
In the event that termination without cause occurs in the final twelve months of
the Term, payments shall continue until the end of the Term, plus an additional
twelve months (ii) Corporation will continue to pay commissions / bonuses as
defined in Section 2.2 of this agreement (iii) Corporation will continue to
provide executive with benefits as defined in Section 2.3 of the agreement with
all shares of Vitalstate Inc. stock being 100% vested at the termination date.
For purposes of this Agreement, a change in control shall be deemed to have
occurred when

                                       5
<PAGE>

any person and all other persons who constitute a group (within the meaning of
Section 13(d)(3) of the Securities Exchange Act or 1934) have acquired direct or
indirect beneficial ownership of 50% or more of Vitalstate Inc.'s outstanding
voting securities. If any circumstance where Sections 4.3 and 4.4 of this
Agreement can both be deemed to be applicable, only this Section 4.4 shall
apply.

5.   MISCELLANEOUS
     -------------

5.1 ASSIGNMENT. Except as provided in this Section 5.1, the Executive and the
Corporation acknowledge and agree that the covenants, terms and provisions
contained in this Agreement and the rights of the parties hereunder cannot be
transferred, sold, assigned, pledged, or hypothecated; provided, however that
this Agreement shall be binding upon and shall enure to the benefit of the
Corporation and any successor to or assignee of all or substantially all of the
business and property of the Corporation. In addition, the Corporation may
assign its rights hereunder to a direct or indirect subsidiary, affiliated
company, or division of the Corporation without the consent of the Executive.

5.2 CAPACITY. The Executive hereby represents and warrants that, in entering
into this Agreement, he is not in violation of any contract or agreement,
whether written or oral, with any other person, moral or physical, firm,
partnership, corporation or any other entity to which he is a party or by which
he is bound and will not violate or interfere with the rights of any other
person, firm, partnership, corporation or other entity.

5.3 ENTIRE AGREEMENT. This Agreement contains the entire agreement between the
parties and shall not be modified except in writing by the parties hereto.
Furthermore, the parties hereto specifically agree that all prior agreements,
whether written or oral, relating to the Services to the Corporation shall be of
no further force or effect from and after the date hereof.

5.4 SEVERABILITY. If any phrase, clause or provision of this Agreement is
declared invalid or unenforceable by a court of competent jurisdiction, such
phrase, clause or provision shall be deemed severable from this Agreement, but
will not effect any other provisions of this Agreement, which otherwise shall
remain in full force and effect. If any restriction or limitation in this
Agreement is deemed to be unreasonable, onerous and unduly restrictive by a
court of competent jurisdiction, it shall not be stricken in its entirety and
held totally void and unenforceable, but shall remain effective to the maximum
extent permissible within reasonable bounds.

5.5 WAIVER. The waiver by the Corporation or the Executive of any breach of any
term or condition of this Agreement shall not be deemed to constitute the waiver
of any other breach of the same or any other term or condition hereof.

5.6 GOVERNING LAW. The parties hereto agree that this Agreement shall be
construed as to both validity and performance and shall be enforced in
accordance with and governed by the laws of New York applicable therein.

                                       6
<PAGE>

     IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be
duly executed as of the date first above written.

                              VITALSTATE INC.

                              By: /s/ Heather Baker
                                  ---------------------------------------
                              Name:   Heather Baker
                              Title:  President and Chief Executive Officer

                              /s/ Terry Giles
                                  ---------------------------------------
                                  Terry Giles

                                       7Letter Agreement

Exhibit 10.31

Dated as of January 1, 2001

 

I. Craig Henderson, M.D.

c/o ACCESS Oncology, Inc.

730 Fifth Avenue, Ninth Floor

New York, NY  10019

Dear Dr. Henderson:

This letter agreement will confirm your employment (“Executive”
or “you”) with Access Oncology, Inc. (the “Corporation”), under the following terms and conditions and for
the following consideration:

1.            Term
of Agreement; Compensation.  (a)        This agreement shall continue until December
31, 2004 (the “Employment Term”), except the term shall be automatically renewed for a period of two years on each
expiration date unless either party provides six months prior written notice of non-renewal to the other party.

(b)           
Executive shall be paid $200,000 per year (the “Base Salary”), payable on a bi-monthly basis in arrears; provided that
Executive’s Base Salary shall be increased by at least 15% annually, with the first adjustment on
January 1, 2002 and thereafter on each January 1 that this Agreement is in effect.  Notwithstanding the foregoing, until the
time that the Executive joins the Corporation on a full-time basis, Executive will receive a percentage of the Base Salary equal to
the percentage of time that the Executive is devoting to the Corporation pursuant to paragraph 2 at the time any Base Salary
payment is due.  Additionally, upon the time that Executive joins the Corporation on a full-time basis and assuming that
corporate resources are adequate to justify such an increase, the Executive’s Base Salary will be increased to a level
commensurate with Executive’s role and experience level.

(c)           
Executive shall be entitled to an annual performance bonus of up to 50% of the Base Salary (the “Performance Bonus”)
based on annual target performance objectives to be agreed upon by the Chairman of Board of Directors and the Executive on or
before the December 15 immediately preceding fiscal year for which the Performance Bonus shall be applicable.  For the fiscal
year ending December 31, 2001, your target performance objectives and bonus amounts will based on the achievement of the stated
overall corporate performance goals for 2001 (and will be agreed upon within 120 days of the date hereof).

(d)            You
shall receive, options (the “Incentive Options”) to purchase 5% of the fully-diluted shares of common stock of the
Corporation outstanding as of the date hereof (including the round of financing currently being conducted) with an exercise price
of $.20 per share, which options shall be exercisable for a 10 year period.  Twenty-five percent of the Incentive Options
shall vest on December 31, 2001 and then equally on a quarterly basis thereafter over the next three-year (3) period while this
Agreement is in effect, such that on December 31, 2004, all such Incentive Options shall be fully vested.  The Incentive
Options shall otherwise be subject to the terms and conditions of the Corporation’s Employee Stock
Option Plan.

(e)            Upon the
occurrence of each Qualified Offering
(as defined in Exhibit B), you shall receive additional options (the “Offering
Options”) to purchase common stock of the Corporation equal to 5% of the shares
of equity securities issued in such Qualified Offering.  Such options shall
have an exercise price equal to the fair market value of the Common Stock on the
closing date of such transaction, shall be exercisable for a 10-year period and
shall otherwise be subject to the terms and conditions of the Corporation’s
Employee Stock Option Plan.  The Offering Options shall vest 25% on the
first anniversary of such grant and the remainder in equal quarterly
installments over the next three years such that all such options shall be vest
on the fourth anniversary of such grant.

(f)            From
time to time, at the discretion of the Board of Directors, you may be eligible for additional stock option grants.

2.  Position and Responsibilities.  Subject to the terms
and conditions set forth herein, the Corporation hereby engages and employs the Executive, and the Executive hereby accepts
engagement and employment, as follows:

	
Timeframe

	
Time

Commitment

	
Title

	
Anticipated Responsibilities

	

January 1, 2001-June 30, 2001

	

25%

	

President

	

The Executive shall be primarily responsible for overseeing and managing the
Corporation’s clinical services division, including, assisting in finalizing the business model, defining the product and
service offerings, developing the model and infrastructure for data management, recruiting and hiring the core team, recruiting top
oncology practices to join OCOG and finding additional trial sponsors interested in utilizing the Corporation’s clinical
services.

During this period, the Executive will also provide assistance to AOI
Communications and AOI Pharmaceuticals on an advisory basis.

Executive will also assist the Corporation in its capital raising
efforts.

 

 

  
	

July 1, 2001-December 31, 2001

	

50%

	

President

	

The Executive will continue to manage the clinical services division. 
Additionally, Executive will gradually during this period takeover the oversight management of the entire services division (OCOG,
AOI Communications and cancereducation.com), such that by the end of 2001, all the senior executives in the services division will
have a direct reporting relationship to Executive (or his designated appointee).

Executive will continue to assist the Corporation in its capital raising
efforts.

	

Thereafter

	

Full-time

(80%+)

	

CEO and

President

	

As CEO & President, Executive shall assume the day-to-day management of
the entire Corporation.  Accordingly, senior executives from the Services Division and AOI Pharmaceuticals will report
directly to the Executive (or his designated appointee).

In turn, Executive will report directly to Michael S. Weiss, Executive
Chairman of the Corporation on the progress of the operating units and collaboratively establish monthly, quarterly and annual
budgets and operating plans as well as the establishment of corporate goals and objectives.

It is anticipated that Michael S. Weiss, Executive Chairman, will maintain
day-to-day management of the Corporation’s in-licensing/partnering business development efforts as well as focusing on
strategic initiatives for the Corporation, including, mergers & acquisitions, joint ventures and capital raising/wall
street.  Executive will assist with and participate in these activities as well.

  

Additionally, Executive shall be appointed to the Board of Directors of the
Corporation at the next in-person Board meeting.

3.           
Vacation.  Upon joining the Corporation on a full-time basis, Executive shall be entitled to four (4) weeks of paid
vacation during each calendar year.

4.           
Non-Competition.  Executive understands and recognizes that his services to the Corporation are special and unique and
agrees that, during the Employment Term and for a period of one (1) year from the date of termination of the Employment Term,
Executive shall not in any manner, directly or indirectly, on behalf of Executive or any person, firm, partnership, joint venture,
corporation or other business entity (“Person”), enter into, engage in or consult for any commercial business that
operates an oncology-focused proprietary product development business, an oncology-focused clinical research business,
oncology-focused site management organization, oncology-focused clinical research network, oncology-focused web site and/or an
oncology-focused medical communications business, in each case which is competitive with the business of the Corporation, either as
an individual for his/her own account, or as a proprietor, partner, member, joint venturer, employee, consultant, agent,
salesperson, officer, director or shareholder (the “Restricted Businesses”) within the geographic area of the
Corporation’s business, which is deemed by the parties to be the United States of America; provided, however, that nothing
shall prevent the Executive from purchasing shares of any company in the public market or for working for a company that conducts a
Restrictive Business, so long as Executive works in a division of such company that is not engaged in a Restricted Business. 
Executive acknowledges and agrees that given the services to be provided hereunder that this non-compete clause is
reasonable.  Notwithstanding the foregoing, the Corporation acknowledges that Executive has continuing obligations to Alza
Corporation and to certain other pharmaceutical companies, medical communications companies and Internet-based companies to perform
certain advisory and speaker activities, and the Corporation explicitly agrees that those activities are outside of this
non-compete agreement.

5.           
Confidential Information.  (a)  Executive agrees that
during the course of the Employment Term or at any time after termination, Executive will keep in strictest confidence and will not
disclose or make accessible to any other person without the prior written consent of the Corporation, the Corporation’s
products, services, business plan, manner of doing business and technology, both current and under development, promotion,
marketing and educational programs, customer and other lists, trade secrets and other confidential and proprietary business
information of the Corporation or any of its clients and third parties including, without limitation, Proprietary Information (as
defined in Section 6) (all the foregoing collectively being referred to herein as the “Confidential
Information”).  Executive agrees:  (i) not to use any such Confidential Information for itself or others, (ii) not
to disclose or publish any of the Confidential Information and (iii) not to take any such material or reproductions thereof from
the Corporation’s facilities at any time during the Employment Term except, in each case, as required in connection with
Executive’s duties to the Corporation.

(b)            Upon
written notice by the Corporation, Executive shall promptly redeliver to the Corporation, or, if requested by the Corporation,
promptly destroy all written or electronic Confidential Information and any other written or electronic material containing any
information included in the Confidential Information (whether prepared by the Corporation, Executive, or a third party), and will
not retain any copies, extracts or other reproductions in whole or in part of such written or electronic Confidential Information
(and upon request certify such redelivery or destruction to the Corporation in a written instrument reasonably acceptable to the
Corporation and its counsel).

6.           
Ownership Of Proprietary Information.  (a) Executive
agrees that all information, materials and/or inventions created, discovered or developed by Executive under this Agreement
(collectively, the “Inventions”), by the Corporation, its subsidiaries, affiliates or licensors or made known to the
Corporation or any of its affiliates by Executive during the Employment Term and information relating to the Corporation’s
customers, suppliers, consultants, and licensees, and/or in which property rights have been assigned or otherwise conveyed to the
Corporation or its affiliates, shall be the sole property of the Corporation or the affiliates, as applicable, and the Corporation
or the affiliates, as the case may be, shall be the sole owner of all patents, copyrights and other rights in connection therewith,
including without limitation the right to make application for statutory protection.  All of the aforementioned information is
hereinafter called “Proprietary Information.”  By way of illustration, but not limitation, Proprietary Information
includes web pages, computer programs, trade secrets, processes, discoveries, structures, inventions, designs, ideas, works of
authorship, copyrightable works, trademarks, copyrights, formulas, data, know-how, show-how, improvements, inventions, product
concepts, techniques, information or statistics contained in, or relating to, marketing plans, strategies, forecasts, blueprints,
sketches, records, notes, devices, drawings, customer lists, patent applications, continuation applications, continuation-in-part
applications, file wrapper continuation applications and divisional applications and information about the Corporation’s or
its affiliates’ employees and/or consultants (including, without limitation, the compensation and job responsibility of such
employees and/or consultants).

(b)           
Executive shall maintain and furnish to the Corporation complete and current records of all such Inventions and disclose to the
Corporation in writing all such Inventions.  Executive:  (i) hereby assigns, sets over and transfers to the Corporation
all of his right, title, and interest in and to such Inventions; and (ii) agrees that Executive and his agents shall, during and
after the period Executive is retained by the Corporation, upon reasonable request of the Corporation, cooperate fully in obtaining
patent, trademark, service mark, copyright or other proprietary protection for such Inventions, all in the name of the Corporation
(but only at Corporation expense), and, without limitation, shall execute all requested applications, assignments and other
documents, and take such other measures as the Corporation shall reasonably request in order to perfect and enforce the
Corporation’s rights in such Inventions, and hereby appoints the Corporation as Executive’s attorney to execute and
deliver any such applications, assignments or other documents on Executive’s behalf in the event that the Executive fails or
refuses to execute and deliver any such applications, assignments or other documents requested by the Corporation.

7.           
Non-Solicitation.  During the Employment Term, and for one (1) year thereafter, Executive shall not, directly or
indirectly, without the prior written consent of the Corporation:  (a) interfere with, disrupt or
attempt to disrupt any past, present or prospective relationship, contractual or otherwise, between the Corporation and any of its
licensees, licensees, clients, customers, suppliers, employees, consultants or other related parties, or (b) solicit or induce for
hire any of the employees, agents, consultants or advisors of the Corporation or any such individual who in the past was employed
or retained by the Corporation, within six (6) months of the termination of said individual’s employment or retention by the
Corporation; provided, however, that this prohibition shall not apply to consultants or advisors so long as
Executive is not in violation of his non-compete agreement and such consultants and advisors do not terminate their relationship
with the Corporation as a result of their involvement with the Executive, or (c) solicit or accept employment or be retained by any
party who, at any time during the Employment Term, was a customer or supplier of the Corporation or any of its affiliates or any
licensor or licensee thereof where such person’s position will be related to a Restricted Business (as such term is defined
in paragraph 4 above); or (d) solicit or accept the business of any customer or supplier of the Corporation or any affiliate of the
Corporation with respect to products similar to those supplied by the Corporation or such affiliate.

8.           
Expenses & Benefits.  (a)  The Corporation will promptly
reimburse Executive for all reasonable and necessary business expenses 
incurred
by him/her in connection with providing the employment services under this
Agreement.

(b)            The
Corporation shall make available to Executive similar health benefits and other
benefits that it makes available to its other senior
executives.

9.           
Termination; Severance and Accelerated Vesting.  (a) Upon your
joining the Corporation on a full-time basis, if thereafter the Corporation 
terminates
your employment without “just cause” (as defined in Exhibit A hereto) or you
terminate your employment for “good reason” (as defined in Exhibit A hereto),
then Executive will be entitled to receive the amounts set forth under paragraph
9(b) below and Executive shall receive one additional year of vesting on all
stock options granted to you; provided, however, if your employment is
terminated in accordance with this paragraph 9(a) within 12 months of a
“Qualified Change in Control” then you shall be entitled to immediate vesting of
all remaining unvested stock options.  Additionally, regardless of such
termination, your stock options shall remain exercisable for the full teen of
such options.

(b)            In the
event your employment is terminated in accordance with paragraph 9(a), you shall receive a lump-sum payment equal to:  (i} one
(1) year’s Base Salary; (ii) any earned and unpaid bonus as of the date of termination; and (iii) any incurred and unpaid
expenses; provided, however, if your employment is terminated in accordance with paragraph 9(a) within 12 months of a
“Qualified Change in Control” then you instead will be entitled to a lump-sum payment equal to:  (x) two (2)
year’s Base Salary; (y) any earned and unpaid bonus as of the date of termination; and (z) any incurred and unpaid
expenses.

(c)            In the
event that your employment is terminated as a result of death or Disability (as defined in Exhibit A) of the Executive, then
Executive or his estate or legal representative shall receive a lump-sum payment equal to (a) Base Salary through the date of
termination, (b) any earned and unpaid bonus and (c) any incurred and unpaid expenses.

10.           
Indemnification.  The Corporation shall defend and indemnify Executive in his capacity as President, Chief Executive
Officer and Director of the Corporation against any and all claims, judgments, damages, liabilities, costs and expenses (including
reasonable attorney’s fees) arising out of, based upon or related to the Executive’s performance of services hereunder,
except to the extent that such claims arise out of Executive’s (a) willful misconduct, (b) bad faith, (c) gross negligence or
(d) reckless disregard of the duties involved in the conduct of Executive’s position.

11.           
Entire Agreement; Waiver.  This Agreement contains the      entire understanding of the
parties with respect to the retention of Executive by the Corporation.  There are no restrictions, agreements, promises,
warranties, covenants or undertakings between the parties with respect to the subject matter herein other than those expressly set
forth herein.  This Agreement may not be altered, modified, or amended except by written instrument signed by the parties
hereto.

12.           
Governing Law.  This Agreement shall be governed by, and construed and interpreted in accordance with, the laws of the
State of New York without regard to such State’s principles of conflict of laws.  The parties hereto consent to the
exclusive jurisdiction of the courts of the State of New York or any district court sitting in the State of New York for any
disputes arising under this letter agreement.

13.           
Headings.  The headings of the Sections are inserted for convenience of reference only and shall not affect any
interpretation of this Agreement.

14.           
Severability of Provisions.  If any provision of this Agreement shall be declared by a court of competent jurisdiction
to be invalid, illegal or incapable of being enforced in whole or in part, such provision shall be interpreted so as to remain
enforceable to the maximum extent permissible consistent with applicable law.  The remaining conditions and provisions or
portions thereof shall nevertheless remain in full force and effect and enforceable to the extent they are valid, legal and
enforceable, and no provision shall be deemed dependent upon any other covenant or provision unless so expressed herein.

 IN WITNESS WHEREOF, the parties hereto have
executed this Letter Agreement as of the day and year first written above.

 

	
EXECUTIVE:

 

by:        /s/ I. Craig Henderson,
M.D.   

Name:  I. Craig Henderson, M.D.

	
CORPORATION:

ACCESS Oncology, Inc.

by:        /s/ Michael S.
Weiss                

Name:  Michael S. Weiss

Title:    Chairman & CEO

 

 

Exhibit A

Certain Definitions

	 Just
Cause.  Any of the following actions by the Executive shall constitute just cause for termination by the Chairman of
the Board of Directors of the Corporation:

	

Material breach by the Executive of the confidentiality, non-compete, ownership
of inventions and non-solicitation covenants contained in this Employment Letter
Agreement; or

  
	

Any action by the Executive constituting willful misconduct in respect of the
Executive’s obligation to the Corporation that has or is likely to result in
material., economic damage to the Corporation; or

  
	

The willful and continual failure or refusal by the Executive to perform his
duties as under this letter employment (other than by reason of death or
Disability (as defined below), or other reasons beyond Executive’s control),
provided such failure or refusal continues for a period of 30 days after receipt
of written notice thereof from the Chairman of the Board of Directors in
reasonable detail of such failure or refusal; or

  
	

Conviction of any crime which involves (i) an intentional
wrongful act or (ii) an act of moral turpitude that (a) is intended to result in substantial personal enrichment of the Executive
at the expense of the Corporation or (b) may have a material adverse impact on the business or reputation of the
Corporation.

  

	 Good
Reason.  Any of the following actions or omissions by the Corporation shall constitute good reason for termination by
Executive:

	

Material breach by the Corporation of any provision of this Employment Letter
Agreement which is not cured by the Corporation within 30 days of notice thereof
from the Executive; or

  
	

A failure to elect or reelect the Executive to the office of President, Chief
Executive Officer and Director of the Corporation or other diminution of the
Executive’s function, duties or responsibilities in each case without the
Executive’s written consent; or

  
	

Reduction in Executive’s Base Salary or incentives or other fringe benefits of a
material economic effect; or

  
	

Termination of the Executive’s employment within 12 months of a “change in
control” (as defined below) if such termination is initiated by the
Corporation (or such successor corporation) without “just cause” or by the Executive for “good reason”
(other than as set forth in this subparagh (D)).  A “change in control,” shall mean either:  (x) a Merger (as
defined below), except for a transaction the principal purpose of which is to change the:  State of incorporation, (y) the
sale, transfer or other disposition of all or substantially all of the assets of the Corporation; or (z) any other corporate
reorganization or business combination (including, but not limited to, a merger in which the Corporation is the surviving entity)
in which more than fifty percent (50%) of the Corporation then outstanding voting stock is transferred to different holders in a
single transaction or a series of related transactions; or

  

	

Relocation of Executive, without his prior consent to a facility or location
that is more than fifty (50) miles away from the Executive’s then present
location.

  

	

Disability.  Shall mean (i) the suffering of any mental or physical illness, disability or incapacity that shall
in all material respects preclude the Executive from performing his employment duties or (ii) the Executive’s absence from
employment by reason of any mental or physical illness, disability or incapacity for a period of four and one-half months during
any nine-month period; provided that such illness, disability or incapacity shall be reasonably determined by the Chairman of the
Board of Directors of the Corporation to be of a permanent nature based on the foregoing standards.

  
	

Merger.  Shall mean a merger or consolidation of the Corporation with any other corporation or entity, other
than a merger or consolidation which would result in the voting securities outstanding immediately prior thereto continuing to
represent (either by remaining outstanding or by being converted into voting securities of the surviving entity) more than fifty
(50%)percent of the total voting power represented by the voting securities of the Corporation or such surviving entity outstanding
immediately after such merger or consolidation.

  
	

 Qualified Offering. Shall mean the sale of securities of the Corporation prior to the earlier to occur of (a)
raising $30 million and (b) the initial underwritten public offering, provided that the price paid for such securities places a
valuation on the Corporation that is greater than the post-offering valuation of the Corporation for the round of financing
immediately preceding such sale of securities.

  
	

Qualified Change in Control.  Shall mean a “change in control”, which places a value on the
Corporation of in excess of $50 million.

  

NYC01/7725055v1

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00064-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00064-of-00352.parquet"}]]